Depression and anxiety are major global health burdens. Although SSRIs targeting the
serotonergic system are prescribed over 200 million times annually, they have variable …

The selective serotonin reuptake inhibitor (SSRI) fluoxetine is widely prescribed for the
treatment of symptoms related to a variety of psychiatric disorders. After chronic SSRI …

The current speed of progress in depression research is simply remarkable. We have
therefore been able to create a second special issue of Molecular Psychiatry, 2020, focused …

Most of the commonly used antidepressants block monoamine reuptake transporters to
enhance serotonergic or noradrenergic neurotransmission. Effects besides or downstream …

Serotonin-releasing fibers depart from the raphe nuclei to profusely innervate the entire
central nervous system, displaying in some brain regions high structural plasticity in …

The incorporation of peripheral biomarkers in the treatment of major depressive disorders
(MDD) could improve the efficiency of treatments and increase remission rate. Peripheral …

Rationale Identification of biomarkers that establish diagnosis or treatment response is
critical to the advancement of research and management of patients with depression …

A metabolomic investigation of depression and chronic fluoxetine treatment was conducted
using a chronic unpredictable mild stress model with C57BL/6N mice. Establishment of the …

Exposure to chronic social isolation (CSIS) and synapse dysfunction have been implicated
in the etiology of major depressive disorder (MDD). Fluoxetine (Flx) has been widely used to …

Aims: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used class of
antidepressants for treating major depression. However, approximately 30% of patients do …